Press Releases
Impulse Dynamics Announces Leadership Changes
Jason Spees Appointed to Chief Executive Officer Shlomi Nachman To Be Chairman and John Liddicoat To Join the Board of Directors Expanding Depth of Medical Device Industry Leadership and Track Record of Driving Commercialization Success With Advanced...
Impulse Dynamics Announces First Implant for CCM-D™ Clinical Trial
World’s First Device Combining CCM Therapy With an ICD in a Single Rechargeable Implant That Treats Both Heart Failure Symptoms and Sudden Cardiac DeathMARLTON, N.J., May 18, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to...
Impulse Dynamics Announces 9,000th Patient Milestone Achieved With CCM® Therapy for Heart Failure
Momentum Continues as Depth of Clinical Experience Expands WorldwideMARLTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a worldwide...
Impulse Dynamics Announces 100th Implant Milestone in China for CCM® Therapy
Experience Continues to Show CCM Therapy Addresses Clinical Need in Treating Heart FailureMARLTON, N.J., November 16, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, announced the...
Impulse Dynamics Announces First International Implants of the Optimizer Smart Mini System in Italy
MARLTON, N.J., JUNE 14, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a commercial-stage medical device company focused on delivering our CCMTM therapy to people with heart failure, announced that the first implants in Europe for the newly launched Optimizer® Smart Mini...
Late-breaking Results Show Efficacy for CCM in Patients With HFpEF
Investigators Report Positive Findings From Feasibility Study of CCM in Heart FailureWith Preserved Ejection Fraction at the European Society of Cardiology Heart Failure 2022 CongressMADRID and MARLTON, N.J., May 23, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global...
Impulse Dynamics Completes $101M Financing Round
Financing To Support Commercial Acceleration of the Optimizer Smart Mini, Enrollment in the Landmark AIM HIGHer Clinical Trial, and Continued Development of a CCM-D Combination DeviceMARLTON, N.J., May 12, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical...
Impulse Dynamics Announces First Implants of Optimizer Smart Mini
Company Is Committed to Innovation for Patients Living With Heart FailureMARLTON, N.J., May 10, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is announcing today the first...
Impulse Dynamics Launches Optimizer Smart Mini
Smaller, Smarter, Long-lasting Device Gives Patients a Reason To Believe There Is a TomorrowMARLTON, N.J., April 29, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud...
Impulse Dynamics Announces 7000th Patient Treated With CCM Reinforcing Significant Clinical Experience
CCM Therapy Addresses an Unmet Clinical Need and Offers Hope to Millions With Heart FailureMARLTON, N.J., April 26, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud...
Impulse Dynamics’ Quality Management System Receives Certification Under European Union Medical Device Regulation
Impulse Dynamics Is Now Among the First US-based Manufacturers of Active Implantable Devices To Receive CertificationMARLTON, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, is pleased...
Impulse Dynamics’ Quality Management System Receives Certification Under European Union Medical Device Regulation
Impulse Dynamics Is Now Among the First US-based Manufacturers of Active Implantable Devices To Receive CertificationMARLTON, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, is pleased...
Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer — Implantable Device Trial to Treat Heart Failure in Higher EF Population
Trial Evaluates FDA-Designated Breakthrough Therapy for Patients Who Lack Treatment OptionsMARLTON, N.J., March 14, 2022 — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the...
Impulse Dynamics Announces Chief Financial Officer Transition
Harriss Currie to Succeed Gerry HainesMARLTON, N.J., January 25, 2022 — Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure, today announced the appointment of Harriss T. Currie as Executive Vice President and Chief Financial...
Impulse Dynamics Appoints Five New Board Members
Impulse Dynamics Appoints Five New Board Members New Directors Bring a Wealth of Relevant Experience MARLTON, N.J., November 11, 2021 — Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of...
Impulse Dynamics Announces First Optimizer Implant in China
Breakthrough CCM Therapy Now Being Implemented in ChinaMARLTON, N.J., November 1, 2021 — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, today announced the first implantation of a patient in China with...
Impulse Dynamics Receives FDA Approval to Modify Labeling for Optimizer Smart Medical Devices
FDA Authorizes Removal of “NSR” From Indications for UseMARLTON, N.J., October 26, 2021 — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the U.S. Food and Drug Administration...
Impulse Dynamics Expands Commercial Leadership Team
MARLTON, N.J., July 19, 2021 — Impulse Dynamics (USA) Inc., a company dedicated to improving the lives of people with heart failure (HF), today announced the appointment of Jason Spees to the position of President, Chief Commercial Officer. Spees, who will be based in...
Impulse Dynamics Receives Approval to Sell Optimizer CCM Devices in China
NMPA Clears the Way for Impulse Dynamics to Deliver Hope for Heart Failure PopulationMARLTON, N.J., February 22, 2021 — Impulse Dynamics, a company dedicated to improving the lives of people with heart failure (HF), today announced that the National Medical Products...
Global Regulatory Organization Certifies Optimizer Smart Device as Compliant for Whole-Body MRI Scans in the EU
Impulse Dynamics Receives Medical Device Approval for European Union to Safely Administer MRI Scans for Heart Failure Patients with Implanted Optimizer Smart DevicesMARLTON, N.J., February 16, 2021 — Impulse Dynamics, an international medical device company dedicated...
Impulse Dynamics Announces FDA Approval for Magnetic Resonance Imaging
FDA Clears Potential Hurdle for Many Heart Failure PatientsMARLTON, N.J., January 20, 2021 — Impulse Dynamics, a company dedicated to improving the lives of people with heart failure (HF), today announced the U.S. Food and Drug Administration (FDA) has approved the...
Impulse Dynamics Closes $60 Million Financing
Funding to Accelerate Clinical and Product Development Pipelines, Commercialization of Optimizer Smart System for Heart FailureMARLTON, N.J., January 12, 2021 — Impulse Dynamics, a company dedicated to helping healthcare providers improve the lives of people with...
Impulse Dynamics Announces First Heart Failure Patient Treated with CCM Therapy in Brazil
Breakthrough Therapy Now Commercially Available in South America’s Most Populous CountryMARLTON, N.J. – January 05, 2021 – Impulse Dynamics, a company dedicated to helping healthcare providers improve the lives of people with heart failure, today announced the first...
Impulse Dynamics Announces Publication of Data from FIX-HF-5C2 Study Evaluating the Two-Lead Optimizer System
Availability of the two-lead device represents a significant advancement in the development of cardiac contractility modulation therapy for patients with heart failureMT. LAUREL, N.J.– April 14, 2020 – Impulse Dynamics, a medical device company dedicated to improving...
Impulse Dynamics Announces First Enrollment in Post-Approval Study of CCM Therapy Delivered by the Optimizer System
Post-Approval Study will evaluate real-world safety and efficacy evidence for breakthrough heart failure therapyMOUNT LAUREL, N.J. – March 17, 2020 Impulse Dynamics, Inc., a company dedicated to improving the lives of people with heart failure, today announced the...
Impulse Dynamics Appoints Medical Director to Leadership Team
Ishu Rao, M.D., brings wealth of clinical expertise during time of rapid company growthMOUNT LAUREL, N.J. – March 10, 2020 Impulse Dynamics, a company dedicated to improving the lives of people with heart failure and developer of the innovative CCM™ therapy delivered...
Impulse Dynamics Secures $80.25 Million Financing
Funding to Accelerate Commercialization of the Optimizer Smart System for Heart FailureMOUNT LAUREL, N.J. – December 3, 2019 – Impulse Dynamics, developer of Optimizer® Smart System for delivering CCM™ therapy, announced the completion of an $80.25 million Series D...
Impulse Dynamics Secures Transitional Pass-through (TPT) Incremental Payment for the Optimizer Smart System
2020 Payment Rules from the Centers for Medicare and Medicaid Services Bring CCM Therapy to Heart Failure Patients in the Outpatient SettingMount Laurel, NJ, November 5, 2019 – Impulse Dynamics, developer of the implantable Optimizer Smart System for delivering...
First Optimizer® Smart Device Implanted in China
Mount Laurel, NJ, November 1, 2019 – On October 29, 2019, the first Optimizer Smart Cardiac Contractility Modulation CCMTM device was implanted in China at the Boao Super Hospital. Impulse Dynamics’ Optimizer Smart is one of the world’s most advanced heart failure...
Impulse Dynamics Announces U.S. FDA Supplemental-PMA Approval of its Next Generation Optimizer® Smart System
Commercial-Ready Device to Deliver Improved Outcomes to Heart Failure PatientsMOUNT LAUREL, N.J. – October 30, 2019 – Impulse Dynamics, developer of the implantable Optimizer Smart System for delivering CCMÔ (Cardiac Contractility Modulation) therapy, announced today...
First Implant in the Kingdom of Saudi Arabia – Continued Global Growth for Impulse Dynamics’ Optimizer IVs Device.
Stuttgart, Germany – August 23rd, 2015 – Impulse Dynamics announced today (23 August, 2015) the first implantation of its Optimizer IVs device in the Kingdom of Saudi Arabia, at the King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Riyadh. The...
Impulse Dynamics announces appointment of Gerald M. Haines as Executive Vice President and Chief Financial Officer
ORANGEBURG, NY, July 8, 2019 — Impulse Dynamics, developer of the implantable Optimizer® Smart System for delivering CCM™ therapy, announced today the appointment of Gerald M. Haines to the position of Executive Vice President and Chief Financial Officer. Mr....
Impulse Dynamics receives FDA approval for breakthrough Optimizer® Smart System delivering CCM™ therapy for treatment of heart failure
Orangeburg, New York, March 21, 2019 – Impulse Dynamics, developer of the implantable Optimizer® Smart System for delivering CCM™ therapy, announced today that it has received approval from the United States Food and Drug Administration for its first-in-class...
Clinical Registry Data and recently published FIX-HF-5C were presented at the Late-Breaking Clinical Trial Session at EHF 2018
Stuttgart, Germany, May 28th, 2018 – Impulse Dynamics Germany, GmbH announced results on “Real World” experience from its European Clinical Registry. The results were presented today by Prof. Gerd Hasenfuß, MD, Professor of Internal Medicine and Director of the Heart...
FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the JACC: Heart Failure
Orangeburg, New York, May 10, 2018 – Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure. The study results were presented by Prof. William Abraham, MD, Professor of...
The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China
Orangeburg, New York & Stuttgart, Germany. December 18, 2017 – The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure. The announcement was made on December 12, 2017 by Impulse...
Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study.
Orangeburg, New York. August 7, 2017 – Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm Continued Access evaluation of the company’s Cardiac...
Impulse Dynamics Completes $45 million Financing Round
Stuttgart, May 11, 2017 – Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round. The equity financing...
Impulse Dynamics Successfully Launches the Optimizer Smart Device for Heart Failure Treatment in Europe
Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are...
Impulse Dynamics Recognized with Frost & Sullivan’s 2016 New Product Innovation Award
September 12, 2016 – Impulse Dynamics, developer of the Optimizer™ IVs implantable device for the treatment of Chronic Heart Failure (CHF), is the recipient of the prestigious Frost & Sullivan 2016 European Chronic Heart Failure Therapy New Product Innovation...
Impulse Dynamics Completes $30 Million Financing Round
Mt. Laurel, New Jersey, May 13 2016 – Impulse Dynamics, developer of the Optimizer™ IVs implantable device for treatment of chronic heart failure (CHF), announced today that the company has closed a $30 million financing round. The equity financing round was led by...
Continued growth within Europe – Impulse Dynamics announces the first implantations of the Optimizer IVs device in the Slovenia.
Stuttgart, Germany, March 2016 - Impulse Dynamics announced the first two implantations of its Optimizer IVs device in Slovenia. The Optimizer IVs is a minimally invasive implantable device designed to treat Chronic Heart Failure (CHF). The device is based on the...
Impulse Dynamics Opens its Hong Kong Sales and Support Office
Hong Kong, China – January 11th, 2016 – Impulse Dynamics NV (Impulse), the developer of the Optimizer™ IVs implantable device, is pleased to announce the official opening of its Hong Kong sales and support office. The Optimizer IVs is a minimally invasive implantable...
Continued Expansion for Impulse Dynamics’ Optimizer™ IVs Device – First Implant in the Emirate of Sharjah (UAE)
Stuttgart, Germany, November 11th, 2015 – Impulse Dynamics reported today the first implantation of its Optimizer IVs device in the Emirate of Sharjah (UAE). The Optimizer IVs is a minimally invasive implantable device designed to treat Chronic Heart Failure (CHF)....
Impulse Dynamics announced the first implantation of the Optimizer IVs device in Poland
Stuttgart, Germany – August 13th, 2015 – Impulse Dynamics announced today (13 August, 2015) the first implantation of its Optimizer IVs device in Poland, at the University Hospital – Central Veterans’ Hospital in Lodz. The implantation was performed by Dr. Krzysztof...
Continued Expansion for Impulse Dynamics Optimizer IVs device – First implantations in Switzerland
Stuttgart, Germany – August 6th, 2015 – Impulse Dynamics, announced today the first implantation of its Optimizer IVs device in Switzerland, continuing the global expansion of its innovative technology. The Optimizer IVs is a minimally invasive implantable device for...
Impulse Dynamics announces the first implantation of the Optimizer IVs device in a patient with a concomitant S-ICD in the United States
Orangeburg, New York – July 28, 2015 – Impulse Dynamics (USA), Inc. announced that Cardiac electrophysiologist, Andrew Kaplan, M.D., FACC, FHRS became the first physician in the United States to implant the Optimizer™ IVs investigational device as part of the...
Impulse Dynamics announced the first implantation of the Optimizer IVs device in China
Stuttgart, Germany – 9 January, 2015 – Impulse Dynamics announced today the first implantation of its Optimizer IVs device in China. The Optimizer IVs is a minimally invasive implantable device designed to treat Chronic Heart Failure (CHF). The device is based on...
Impulse Dynamics announced the first implantation of the Optimizer IVs device in Russia
Stuttgart, Germany – December, 2014 – Impulse Dynamics announced the first implantation of its Optimizer IVs device in Russia. The Optimizer IVs is a minimally invasive implantable device designed to treat Chronic Heart Failure (CHF). The device is based on novel...
Tag Cloud
Subscribe to
News Updates
Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for our news topics.